1. Scrip
  2. >>Business

Mylan Plans To Compete In US HIV Market With Two Fixed-Dose Combos

 
• By Joseph Haas

Generics firm will launch single-tablet regimens of older HIV drugs not otherwise available as combos in US, with discounted pricing.

HIV-AIDS pills_1200x675

Having supplied HIV treatment regimens to more than 8m patients worldwide in 2017, Mylan NV now is turning its attention to the US with a pair of single-tablet combination regimens recently approved by the US FDA. It seems likely that the generics titan will focus mainly on Medicaid and other economically disadvantaged patient groups with a strategy of pricing its regimens below what competitors like Gilead Sciences Inc. and ViiV Healthcare are charging for their combination pills.

Mylan announced on March 2 that it will launch the three-drug combo Symfi Lo in the coming weeks, with two-drug...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 
• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.

Executives On The Move: New CMOs At Instil Bio, Nkarta & Catalyst Pharma

Recent moves in the industry include changes at the top at iOnctura and Orca Bio, plus Sutro Biopharma, Tenpoint Therapeutics and Helix BioPharma get new CFOs.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 
• By Sushmita Panda

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.